Abstract

BackgroundThe association between oral contraceptive (OC) use and long-term mortality remains uncertain and previous studies have reported conflicting findings. We aim to assess the long-term impact of OC use on all-cause and cancer-specific mortality.MethodsOut of 49,259 participants, we analysed data on 2120 (4.3%) women diagnosed with first primary breast cancer between 1993 and 2012, in the Swedish Women’s Lifestyle and Health Study. Kaplan–Meier plots were used to graph the hazard of mortality in association with oral contraceptives use, stage of disease and hormone receptors status at diagnosis. Cox proportional hazard model were used to estimate hazard ratios (HR) between OC use and all-cause mortality. The same association was studied for breast cancer-specific mortality by modelling the log cumulative mortality risk, adjusting for clinical stage at diagnosis, hormone receptor status, body mass index and smoking.ResultsAmong 2120 women with breast cancer, 1268 (84%) reported ever use of OC and 254 died within 10 years of diagnosis. The risk of death for OC ever-users relative to never-users was: HR = 1.13 (95% CI: 0.66–1.94) for all-cause mortality and HR = 1.29 (95% CI: 0.53–3.18) for breast cancer-specific mortality. A high percentage of women (42.9%) were diagnosed at early stage disease (stage I).ConclusionsAmong women with primary breast cancer, OC ever-users compared to never- users did not have a higher all-cause or breast cancer specific-mortality, after the adjustment of risk factors.

Highlights

  • The association between oral contraceptive (OC) use and long-term mortality remains uncertain and previous studies have reported conflicting findings

  • The Swedish Women’s Lifestyle and Health (WLH) cohort was designed to study the role of hormonal contraceptives in relation to breast cancer in Norway and Sweden, populations with high prevalence of OC use and high breast cancer incidence rates [14, 17]. Using this population-based sample of Swedish women, we examine the association between OC use on both allcause and breast cancer-specific mortality among women diagnosed with breast cancer between 1993 and 2013

  • Among women with TNM stage, 42.9% were diagnosed with stage disease (stage I) disease, 33.9% with stage II and 3.8% with stage III and IV; stages II, III & IV were combined for subsequent analyses

Read more

Summary

Introduction

The association between oral contraceptive (OC) use and long-term mortality remains uncertain and previous studies have reported conflicting findings. Western Europe has the second highest incidence rate of breast cancer worldwide; in Sweden, the age-adjusted incidence rate is approximately 81.4/100,000 women [2, 3]. The International Agency for Research on Cancer published a monograph in 2007, in which a scientific specialist review panel agreed that there was sufficient evidence for an association between OC use and breast cancer risk in humans [4]. This assessment found inconsistent results for women who had ever used OC versus never-users. The increased risk was only noted for women who were current or recent OC users, those who were less than 35 years of age at diagnosis [4]

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call